Nivestim (Filgrastim)

Filgrastim binds to the granulocyte colony‑stimulating factor receptor on hematopoietic progenitor cells, activating signaling pathways that drive the proliferation and maturation of neutrophil precursors, thereby increasing circulating neutrophil counts and enhancing the body’s innate immune defense.

The dose of Nivestim is individualized by the prescribing clinician based on the patient’s weight, indication, and clinical response. Healthcare professionals determine the exact amount and frequency according to established treatment guidelines.

Safety data for filgrastim in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Nivestim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Nivestim contains the same recombinant filgrastim molecule found in other G‑CSF brands. Clinical efficacy and safety are comparable, while differences may exist in manufacturing processes, packaging, and pricing. Choice of product often depends on supplier availability, cost considerations, and institutional preferences.

Nivestim must be stored refrigerated at 2‑8 °C, protected from light. It should not be frozen or shaken. If temporary storage at room temperature is unavoidable, the product may remain stable for a limited period as indicated on the label.

Nivestim is given by subcutaneous injection or intravenous infusion, as directed by the prescriber. The injection site is typically the abdomen or thigh for subcutaneous administration, and aseptic technique must be followed to prevent contamination.

Serious risks include splenic rupture, acute respiratory distress syndrome, severe allergic reactions such as anaphylaxis, and uncontrolled leukocytosis. Patients should be monitored closely for signs of abdominal pain, breathing difficulty, rash, or unusually high white‑blood‑cell counts.

Nivestim is contraindicated in individuals with known hypersensitivity to filgrastim or any of its excipients. Caution is also advised for patients with pre‑existing splenomegaly, active leukemia, or uncontrolled infections, and the drug should be avoided unless a prescriber determines it is essential.